id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-P-0366-0005,FDA,FDA-2005-P-0366,Citizen Petition from Keller and Heckman LLP on behalf of Biovail Corporation,Other,Citizen Petition,2010-03-17T04:00:00Z,2010,3,2010-03-17T04:00:00Z,,2025-04-24T18:52:49Z,,0,0,090000648044af2c
FDA-2005-P-0366-0006,FDA,FDA-2005-P-0366,Tab 2 - Summary Report of Study No. AK1BOVAIL2548 re: Citizen Petition from Keller and Heckman LLP on behalf of Biovail Corporation,Other,Background Material,2010-03-17T04:00:00Z,2010,3,2010-03-17T04:00:00Z,,2025-04-24T19:31:26Z,,0,0,090000648044af2f
FDA-2005-P-0366-0007,FDA,FDA-2005-P-0366,Letter from Keller and Heckman LLP to FDA DDM,Other,Letter(s),2010-03-17T04:00:00Z,2010,3,2010-03-17T04:00:00Z,,2025-04-24T19:33:22Z,,0,0,090000648044af44
FDA-2005-P-0366-0004,FDA,FDA-2005-P-0366,Petition Approval from FDA/Associate Commissioner for Policy and Planning to Keller and Heckman LLP,Other,Approval,2006-12-18T05:00:00Z,2006,12,,,2025-04-24T18:45:27Z,,0,0,090000648044af45
FDA-2005-P-0366-0003,FDA,FDA-2005-P-0366,FDA/Center for Drug Evaluation and Research to Keller and Heckman LLP - Letter,Other,LET-Letter,2006-06-12T04:00:00Z,2006,6,,,2013-07-27T20:43:33Z,,0,0,090000648044af43
FDA-2005-P-0366-0002,FDA,FDA-2005-P-0366,Acknowledgement Letter from FDA DDM to Keller and Heckman LLP,Other,Acknowledgement Letter/Receipt,2005-12-20T05:00:00Z,2005,12,,,2025-04-24T18:29:38Z,,0,0,090000648044af31
FDA-2005-P-0366-0001,FDA,FDA-2005-P-0366,Acknowledgement Letter from FDA DDM to Keller and Heckman LLP,Other,Acknowledgement Letter/Receipt,2005-12-20T00:00:00Z,2005,12,,,2025-05-09T01:17:11Z,,0,0,090000648044aec8